CO-FOUNDER

Adam is a Professor of Haematology and a member of the Radcliffe Department of Medicine at the University of Oxford. A clinician scientist, his research group at the MRC Weatherall Institute of Molecular Medicine is furthering the understanding of how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies, with a particular interest in the development and application of single cell genomics techniques to analyse malignant stem cell populations.

CO-FOUNDER

Beth is an Associate Professor of Haematology and CRUK Advanced Clinician Scientist and member of the Radcliffe Department of Medicine at the University of Oxford. She leads a research group in the MRC Weatherall Institute of Molecular Medicine focused on the biology of platelet-producing cells called megakaryocytes, and their role in cancer and bone marrow fibrosis. Her research applies state-of-the-art single cell ‘omics’ to identify novel targets for therapy.

CHAIRMAN

Mark is an experienced biopharmaceutical executive with extensive research experience and a track record of innovation and execution. He is an expert in antibody engineering and immunology with more than a dozen granted patents and >40 peer reviewed publications. Mark has held multiple industry roles, including Director of Antibody Discovery at Crucell NV and COO and CSO of Merus BV. He is currently part-time COO/CSO of Gadeta BV, advises Chiton Rocks and serves on the Board of Ona Therapeutics.

CHIEF SCIENTIFIC OFFICER

Ed has nearly 20 years of working on innovative approaches to early drug discovery. He has held industry positions at AstraZeneca where he pioneered the use of high throughput imaging for drug discovery screens before moving to become Director of Assay Development and High Throughput Screening at the Genomics Institute of the Novartis Research Foundation (GNF). Prior to joining Alethiomics as its CSO he was Chief Technology Officer at the oncology focused biotech Carrick Therapeutics for 5 years.